Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 21 November 2013 | By Alexander Gaffney, RAC
The Center for Biologics Evaluation and Research (CBER) has just published a new draft guidance document intended to clarify the premarket notification, or 510(k), process for certain types of test kits used to match donors and recipients during transfusions and transplantations.
The test kits in question are known as nucleic acid-based human leukocyte antigen (HLA) test kits, which are used to ensure compatibility between a donor of human cells, tissues, tissue-based products or organs and their eventual host. Non-compatible organs may be rejected by the immune system of the recipient or result in a condition known as graft-versus-host disease in which transplanted immune cells attack the new host.
The guidance comes at a time when the science behind HLA test kits is growing "increasingly complex," FDA observed.
"Testing has evolved from serology and cell-based methods with little instrumentation to deoxyribonucleic acid (DNA) based and multiplex assays that use complex instruments and software," FDA recalled. Regulators also noted the "high degree of polymorphism" and "rare phenotypes" associated with the HLA system, and said they represented "significant and unique challenges" to obtaining regulatory approval.
And those challenges can be amplified by the 510(k) submission system, which relies more on the history of similar devices to prove safety and efficacy than on new data submitted with respect to a new device.
FDA's draft guidance, Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation, makes numerous recommendations to industry.
FDA will be accepting comments on the guidance until 18 February 2014.
Tags: draft guidance